Patents by Inventor Joseph Herman Krushinski, Jr.

Joseph Herman Krushinski, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8962654
    Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: February 24, 2015
    Assignee: Eli Lilly and Company
    Inventors: Christopher David Beadle, David Andrew Coates, Junliang Hao, Joseph Herman Krushinski, Jr., Matthew Robert Reinhard, John Mehnert Schaus, Craig Daniel Wolfangel
  • Publication number: 20140357664
    Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
    Type: Application
    Filed: May 27, 2014
    Publication date: December 4, 2014
    Applicant: Eli Lilly and Company
    Inventors: Christopher David BEADLE, David Andrew COATES, Junliang HAO, Joseph Herman KRUSHINSKI, JR., Matthew Robert REINHARD, John Mehnert SCHAUS, Craig Daniel WOLFANGEL
  • Patent number: 8168659
    Abstract: Compounds and pharmaceutical compositions comprising compounds of the Formula as CB1 receptor inverse agonists useful for reducing body weight in mammals, treating cognitive impairment associated with schizophrenia, and mitigating treatment emergent weight gain observed during treatment with antipsychotics.
    Type: Grant
    Filed: October 22, 2007
    Date of Patent: May 1, 2012
    Assignee: Eli Lilly and Company
    Inventors: David Scott Coffey, Jingdan Hu, Stacy Jo Keding, Joseph Herman Krushinski, Jr., John Mehnert Schaus, David Edward Tupper
  • Publication number: 20090275618
    Abstract: Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB1 receptors via an inverse agonism mechanism which are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.
    Type: Application
    Filed: October 22, 2007
    Publication date: November 5, 2009
    Inventors: David Scott Coffey, Jingdan Hu, Stacy Jo Keding, Joseph Herman Krushinski, JR., John Mehnert Schaus, David Edward Tupper
  • Patent number: 7230011
    Abstract: The present invention relates to compounds of formula I: which are antagonists of 5-HT6 receptor.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: June 12, 2007
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Michael Edward Flaugh, James Ronald Gillig, Lawrence Joseph Heinz, Joseph Herman Krushinski, Jr., Bin Liu, Marta Maria Pineiro-Nunez, John Mehnert Schaus, John Stanley Ward
  • Patent number: 7214673
    Abstract: Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C1-4) alkylene optionally substituted with OH, methoxy, ethoxy, or F; Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic, or bicyclic heteroaromatic; R1 is hydrogen or (C1-4) alkyl optionally substituted with OH, OR3, or OCH2CH2OH, wherein R3 is (C1-2) alkyl; R2 is H, (C1-6) alkyl, halogen, fluorinated (C1-6) alkyl, OR4, SR4, NO2, CN, COR4, CONR5R6, SO2NR5R6, NR5R6, NR5COR4, NR5SO2R4, or optionally substituted phenyl, wherein R4 is hydrogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, or optionally substituted phenyl, R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl; Z is one or two substituents independently selected from hydrogen, halogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, SO2NR8R9, NR8SO2R
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: May 8, 2007
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Joseph Herman Krushinski, Jr., Yvan Le Huerou, Marta Maria Pineiro-Nunez, Kevin Michael Ruley, John Mehnert Schaus, Dennis Charles Thompson, David Edward Tupper, Ying Chen, Margaret Mary Faul, Vincent Patrick Rocco
  • Patent number: 6777428
    Abstract: The present invention relates to a compound of formula I and a process for making: or a pharmaceutical acid addition salt thereof; which are useful for activating 5-HT1F receptors and inhibiting neuronal protein extravasation in a mammal.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: August 17, 2004
    Assignee: Eli Lilly and Company
    Inventors: Joseph Herman Krushinski, Jr., Vincent Mancuso, Freddy Andre Napora, John Mehnert Schaus
  • Patent number: 6133290
    Abstract: The present invention relates to a compound of formula I: ##STR1## or a pharmaceutical acid addition salt thereof; which are useful for activating 5-HT.sub.1F receptors and inhibiting neuronal protein extravasation in a mammal.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: October 17, 2000
    Assignee: Eli Lilly and Company
    Inventors: Joseph Herman Krushinski, Jr., John Mehnert Schaus
  • Patent number: 5962474
    Abstract: This invention provides novel 5-HT.sub.1F agonists of Formula I ##STR1## where A--B, R,R.sup.1 and X are as defined in the specification, which are useful for the treatment of migraine and associated disorders.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: October 5, 1999
    Assignee: Eli Lilly and Company
    Inventors: James Edmund Audia, Bruce Anthony Dressman, James Joseph Droste, James Erwin Fritz, Stephen Warren Kaldor, Daniel James Koch, Joseph Herman Krushinski, Jr., Jeffrey Scott Nissen, Vincent Patrick Rocco, John Mehnert Schaus, Dennis Charles Thompson
  • Patent number: 5708008
    Abstract: This invention provides novel 5-HT.sub.1F agonists of Formula I ##STR1## where A--B, R, R.sup.1 and X are as defined in the specification, which are useful for the treatment of migraine and associated disorders.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: January 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: James Edmund Audia, Bruce Anthony Dressman, James Joseph Droste, James Erwin Fritz, Stephen Warren Kaldor, Daniel James Koch, Joseph Herman Krushinski, Jr., Jeffrey Scott Nissen, Vincent Patrick Rocco, John Mehnert Schaus, Dennis Charles Thompson